Key result
Orforglipron lowers HbA1c more than oral semaglutide at 52 weeks in T2D uncontrolled by metformin.
Answers are grounded in this paper and cite their sources.
Orforglipron may be preferred over oral semaglutide for HbA1c reduction on metformin; extends direct RCT comparisons of oral GLP-1 agonists.
CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].
No takes yet. Share an insight, caveat, or question.
Darren Lau (2026) studied this question. Orforglipron reduced HbA1c more than oral semaglutide at 52 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Synapse has enriched 10 related papers. Consider them for comparative context: